Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck

Affiliations

Comment

Oliver Klein. JAMA Oncol. 2024.

. 2024 Jan 1;10(1):143-144.

doi: 10.1001/jamaoncol.2023.5404.

¹ Olivia Newton-John Cancer Research Institute, Olivia Newton-John Cancer Centre, Austin Health, Heidelberg, Victoria, Australia.

No abstract available

Comment in

Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck-Reply.
Harrington KJ, Haddad R. Harrington KJ, et al. JAMA Oncol. 2024 Jan 1;10(1):144-145. doi: 10.1001/jamaoncol.2023.5407. JAMA Oncol. 2024. PMID: 37991775 No abstract available.

Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.
Harrington KJ, Ferris RL, Gillison M, Tahara M, Argiris A, Fayette J, Schenker M, Bratland Å, Walker JWT, Grell P, Even C, Chung CH, Redman R, Coutte A, Salas S, Grant C, de Azevedo S, Soulières D, Hansen AR, Wei L, Khan TA, Miller-Moslin K, Roberts M, Haddad R. Harrington KJ, et al. JAMA Oncol. 2023 Jun 1;9(6):779-789. doi: 10.1001/jamaoncol.2023.0147. JAMA Oncol. 2023. PMID: 37022706 Free PMC article.